Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
ANGLE plc
AGLANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology. In addition, the company offers laboratory services, including enumeration of epithelial and mesenchymal CTC populations; Portrait Flex, an immunofluorescence assay for the identification of epithelial, mesenchymal, and epithelial-to-mesenchymal transition; DNA damage response; Portrait PD-L1, evaluates CTCs; and custom CTC assays. ANGLE plc has a strategic partnership with Bio View Ltd to develop a human epidermal growth factor receptor 2 assay kit for breast cancer; and agreement with NuProbe USA, Inc. to use its proprietary pan-cancer next generation sequencing (NGS) panel. The company was founded in 1994 and is based in Guildford, the United Kingdom. Address: Surrey Research Park, Guildford, United Kingdom, GU2 7AF
Analytics
Preço Alvo de Wall Street
5 399.53 GBXRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave AGL
Análise de Dividendos AGL
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos AGL
Avaliação de ações AGL
Relatório AGL
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |